In a move that signals a significant leap forward for microbiome science, Clinical Microbiomics A/S, a leader in microbiome analysis, has just announced its acquisition of DNASense ApS, a trailblazing Danish company known for its advanced long-read DNA and RNA sequencing technologies.
This strategic acquisition is set to reshape the landscape of microbiome research, extending its applications far beyond human health into new realms such as agriculture, industry, and environmental studies.
Founded on the principles of innovation and excellence, Clinical Microbiomics has carved a niche for itself in the global microbiome sector. With this latest acquisition, the company is not just expanding its technological arsenal but is also venturing into uncharted territories, promising to bring groundbreaking insights into the complex interplay of microbial communities across various ecosystems.
At the heart of this acquisition is the cutting-edge long-read sequencing technology pioneered by DNASense. This technology allows scientists to sequence longer fragments of DNA and RNA, thereby offering a more detailed and comprehensive view of microbial genomes. This enhancement in sequencing capabilities is expected to unravel the intricate dynamics of microbial ecosystems, paving the way for revolutionary discoveries in microbiome research.
H. Bjørn Nielsen, the Chief Scientific Officer at Clinical Microbiomics, expressed his enthusiasm for the acquisition, highlighting the synergy it creates with their existing bioinformatics capabilities. “By integrating DNASense’s pioneering long-read technology into our toolkit, we’re set to delve deeper into the microbiome’s complexities, accelerating groundbreaking discoveries that could transform our understanding of microbial ecosystems,” he remarked.
Mads Søndergaard, CEO of DNASense, shared his optimism about the merger, emphasizing the expanded bioinformatics capabilities and the enhanced service quality that the partnership will bring. “This pivotal moment marks a new chapter for DNASense, where our combined expertise will enable us to offer unparalleled insights into microbial ecosystems across various domains, including environmental, agricultural, and industrial microbiomes,” Søndergaard stated.
This acquisition is a testament to Clinical Microbiomics’ ambitious strategy to build a comprehensive ecosystem of microbiome services that cater to a wide array of applications across human, animal, and environmental fields. The merger is poised to open up new market segments, further cementing Clinical Microbiomics’ position as a global leader in microbiome innovation and service.
The story of Clinical Microbiomics is one of relentless pursuit of excellence and innovation. From its inception in 2015, the company has been at the forefront of microbiome science, continuously expanding its capabilities through strategic acquisitions like MS-Omics and CosmosID. With DNASense now part of its family, Clinical Microbiomics is set to embark on a new journey, expanding the horizons of microbiome science and its applications.
As the microbiome revolution continues to unfold, Clinical Microbiomics stands ready to lead the charge, armed with world-class expertise and a vision to unlock the full potential of microbiome science for a healthier and more sustainable world. The story of this acquisition is not just a business transaction; it’s a bold step towards a future where the mysteries of the microbiome are fully understood and harnessed for the greater good.
